THAP2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 5.2617021850665E-11 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.96389999995716E-06 |
Normal-vs-Stage2 |
4.814200E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.220020E-02 |
Stage1-vs-Stage2 |
7.147700E-02 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
7.125400E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
1.039450E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
3.00559999111272E-09 |
Normal-vs-AfricanAmerican |
3.496400E-01 |
Normal-vs-Asian |
6.626100E-02 |
Caucasian-vs-AfricanAmerican |
8.494600E-01 |
Caucasian-vs-Asian |
7.001600E-01 |
AfricanAmerican-vs-Asian |
6.854800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
1.97230999999798E-05 |
Normal-vs-Female |
1.62230000000374E-06 |
Male-vs-Female |
7.958000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.679860E-03 |
Normal-vs-Extreme_Weight |
5.65009999999866E-05 |
Normal-vs-Obese |
2.641100E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
8.837800E-01 |
Normal_Weight-vs-Obese |
5.605000E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
4.399600E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.965850E-01 |
Normal-vs-Age(41-60Yrs) |
2.983000E-04 |
Normal-vs-Age(61-80Yrs) |
1.32860000001678E-06 |
Normal-vs-Age(81-100Yrs) |
3.864600E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.400300E-02 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.424000E-02 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.137400E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.801800E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.063400E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.147400E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
7.432100E-02 |
Normal-vs-Grade 3 |
8.716300E-02 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
3.914800E-01 |
Grade 2-vs-Grade 4 |
7.432100E-02 |
Grade 3-vs-Grade 4 |
8.716300E-02 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
4.47819999971344E-08 |
Normal-vs-N1 |
3.596200E-02 |
N0-vs-N1 |
7.263800E-01 |
|
|